Advanced Search
MyIDEAS: Login

The Direct Medical Costs Associated with Suspected Heparin-Induced Thrombocytopenia

Contents:

Author Info

  • Natasha Nanwa

    (Graduate Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada)

  • Nicole Mittmann

    (HOPE Research Centre, Division of Clinical Pharmacology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada)

  • Sandra Knowles

    (Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada)

  • Claudia Bucci

    (Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Division of Clinical Pharmacology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada)

  • Rita Selby

    (Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Clinical Pathology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada)

  • Neil Shear

    (Division of Clinical Pharmacology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada)

  • Scott E. Walker

    (Graduate Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada)

  • William Geerts

    (Department of Medicine, University of Toronto, Toronto, Ontario, Canada)

Registered author(s):

    Abstract

    Background: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction associated with heparin exposure. Sunnybrook Health Sciences Centre, a tertiary-care adult academic hospital, has cared for an average of 100 cases of suspected HIT per year. Although the management of suspected HIT is resource intensive, few studies have assessed the cost burden associated with HIT, and none have assessed the costs of suspected HIT. Objective: The objective of this study was to identify and quantify the direct medical costs associated with suspected (confirmed and negative) HIT at a hospital in Canada. Methods: A cost-of-illness analysis was conducted in patients with suspected HIT during 2005. Resource utilization variables included (i) laboratory tests to investigate HIT; (ii) HIT-safe anticoagulant use; (iii) diagnostic imaging related to HIT or its treatment; and (iv) additional hospital days attributed to HIT. The average costs per case of confirmed HIT, confirmed HIT with thrombosis (HITT) and negative HIT were calculated in $Can, year 2007 values. Results: Confirmed HITT cases incurred substantially greater costs ($Can34 155, range 358-202 069; n - 12) than confirmed HIT cases without thrombosis ($Can4575, range 39-16 373; n - 8). The average cost of care for a negative HIT case was $Can119 (range 39-4181; n - 88). Conclusions: This is the first study to quantify the costs associated with suspected HIT cases. These cases increase the costs of hospital care and provide further justification for HIT prevention strategies.

    Download Info

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
    File URL: http://PharmacoEconomics.adisonline.com/pt/re/pec/pdfhandler.00019053-201129060-00005.pdf
    Download Restriction: Pay per view

    File URL: http://PharmacoEconomics.adisonline.com/pt/re/pec/fulltext.00019053-201129060-00005.htm
    Download Restriction: Pay per view

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Bibliographic Info

    Article provided by Springer Healthcare | Adis in its journal PharmacoEconomics.

    Volume (Year): 29 (2011)
    Issue (Month): 6 ()
    Pages: 511-520

    as in new window
    Handle: RePEc:wkh:phecon:v:29:y:2011:i:6:p:511-520

    Contact details of provider:
    Web page: http://pharmacoeconomics.adisonline.com/

    Related research

    Keywords: Anticoagulants; Antithrombotics; Cost-of-illness; Heparin; Heparin-induced-thrombocytopenia-and-thrombosis-syndrome.;

    Find related papers by JEL classification:

    References

    No references listed on IDEAS
    You can help add them by filling out this form.

    Citations

    Lists

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    Statistics

    Access and download statistics

    Corrections

    When requesting a correction, please mention this item's handle: RePEc:wkh:phecon:v:29:y:2011:i:6:p:511-520. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.